Prognostic value of serial lactate levels in septic patients with and without shock.


Journal

Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418

Informations de publication

Date de publication:
11 2019
Historique:
received: 07 05 2019
accepted: 11 09 2019
pubmed: 27 9 2019
medline: 20 5 2020
entrez: 27 9 2019
Statut: ppublish

Résumé

To analyze the prognostic value of lactate levels for day-7 and in-hospital mortality, in septic patients with and without shock. In the period November 2011-December 2016, we enrolled 268 patients, admitted to our High-Dependency Unit with a diagnosis of sepsis. Lactate dosage was performed at ED-HDU admission (T0), after 2 h (T2), 6 h (T6) and 24 h (T24); lactate clearance was calculated at T2 and T6 [T2: ((LAC T0-LAC T2/LAC T0)*100)]; T6: [(LAC T0-LAC T6/LAC T0)*100]. The end-points were day-7 and in-hospital mortality. At every evaluation, the lactate level was higher in patients with shock than in those without (T0 3.8 ± 3.8 vs 2.4 ± 2.1; T6 2.9 ± 3.2 vs 1.6 ± 1.1; T24 3.0 ± 4.4 vs 1.4 ± 0.9 meq/L, all p < 0.001). Among patients with shock, an analysis for repeated measures confirmed a more marked lactate level reduction in survivors compared with non-survivors, both by day-7 and in-hospital mortality (p = 0.057 and p = 0.006). A Kaplan-MeIer analysis confirmed a significantly better day-7 survival in patients with T6 (with shock 86% vs 70%; without shock 93% vs 82, all p < 0.05) and T24 (with shock 86% vs 70%; without shock 93% vs 82, all p < 0.05) lactate ≤ 2 meq/L, compared with patients with higher levels. A T6 lactate clearance > 10% was more frequent among in-hospital survivors in the whole study population (57% vs 39%) and in patients with shock (74% vs 46%, all p < 0.05). Higher lactate levels and decreased clearance were associated with an increased short-term and intermediate-term mortality regardless of the presence of shock.

Identifiants

pubmed: 31555948
doi: 10.1007/s11739-019-02196-z
pii: 10.1007/s11739-019-02196-z
doi:

Substances chimiques

Lactic Acid 33X04XA5AT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1321-1330

Références

JAMA. 2010 Feb 24;303(8):739-46
pubmed: 20179283
Lancet. 2005 Mar 5-11;365(9462):871-5
pubmed: 15752531
Crit Care Med. 2018 Jun;46(6):997-1000
pubmed: 29767636
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Crit Care. 2016 Aug 13;20(1):257
pubmed: 27520452
Intern Emerg Med. 2019 Apr;14(3):459-466
pubmed: 30535649
Eur J Emerg Med. 2014 Aug;21(4):254-9
pubmed: 23970100
Crit Care. 2011;15(5):R242
pubmed: 22014216
Crit Care. 2010;14(5):R182
pubmed: 20942957
Shock. 2015 Jan;43(1):55-61
pubmed: 25186838
Curr Opin Crit Care. 2012 Jun;18(3):267-72
pubmed: 22517402
Shock. 2005 Jun;23(6):488-93
pubmed: 15897799
Crit Care Med. 2018 Jun;46(6):e489-e495
pubmed: 29432347
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
Crit Care. 2011;15(5):R229
pubmed: 21951322
Am J Med Sci. 2018 Aug;356(2):97-102
pubmed: 30219168
Intensive Care Med. 2016 Feb;42(2):202-10
pubmed: 26556617
Curr Opin Crit Care. 2006 Aug;12(4):315-21
pubmed: 16810041

Auteurs

Francesca Innocenti (F)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy. innocenti.fra66@gmail.com.

Federico Meo (F)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Irene Giacomelli (I)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Camilla Tozzi (C)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Maria Luisa Ralli (ML)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Chiara Donnini (C)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Irene Tassinari (I)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Francesca Caldi (F)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Maurizio Zanobetti (M)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Riccardo Pini (R)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Francesca Innocenti, Lg. Brambilla 3, 50134, Firenze, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH